Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

54.95 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,738
Open 54.95
Bid (Size) 54.78 (100)
Ask (Size) 54.99 (100)
Prev. Close 54.95
Today's Range 54.95 - 54.95
52wk Range 42.52 - 62.89
Shares Outstanding 2,222,113,553
Dividend Yield 4.59%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks ↗
Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x. 
Via The Motley Fool
Topics Intellectual Property

Performance

YTD
+2.8%
+2.8%
1 Month
-4.2%
-4.2%
3 Month
-11.9%
-11.9%
6 Month
+11.7%
+11.7%
1 Year
+12.6%
+12.6%

More News

Read More
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Surging Stock with Promising Prospects and 2 We Ignore
Via StockStory
News headline image
Looking to Buy Bristol Myers Squibb Stock on the Dip? Read This First. ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
From Bristol Myers Squibb
Via Business Wire
News headline image
The Most Undervalued Healthcare Stock in the S&P 500 Right Now ↗
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
1 Profitable Stock to Keep an Eye On and 2 We Brush Off
Via StockStory
Topics Energy
News headline image
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
From Bristol Myers Squibb
Via Business Wire
News headline image
3 High-Yielding Dividend Stocks Trading at Dirt Cheap Valuations ↗
Via The Motley Fool
News headline image
10 Years Later: 5 Winners in a Thinking World ↗
Via The Motley Fool
News headline image
2 Large-Cap Stocks to Consider Right Now and 1 We Turn Down
Via StockStory
News headline image
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
From Pacira BioSciences
Via GlobeNewswire
News headline image
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q1 Earnings?
Via StockStory
Topics Stocks
News headline image
Is Bristol Myers Squibb Stock Overvalued at Nearly $60? A Reality Check for Value Investors. ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb Touts Pipeline Gains as Shareholders Back Board at Annual Meeting ↗
Via MarketBeat
News headline image
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol-Myers Squibb’s Q1 Earnings Call: Our Top 5 Analyst Questions
Via StockStory
Topics Earnings
News headline image
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Healthcare Stock with Competitive Advantages and 2 Facing Challenges
Via StockStory

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 54.95
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 06/01/26 07:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 122.11B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 122B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.